Developer docs
API playgroundTry for free, no card

Search company profiles

Alys Pharmaceuticals

Full company profile

uuid0000lqe

Namestring
Alys Pharmaceuticals
Legal namestring
Alys Pharmaceuticals, Inc.
Websiteurl
alyspharma.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company focused exclusively on immuno-dermatology, founded in February 2024 through the strategic merger of six asset-centric Medicxi portfolio companies (Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences, and Vimela Therapeutics) with a $100 million seed financing from Medicxi. The company is headquartered in Boston, Massachusetts, with European operations in the Geneva/Lausanne area and operates through six wholly-owned subsidiaries that each maintain a distinct technology platform: siRNA-lipid conjugates (Aldena), mast cell-selective bispecific antibodies (Granular), intraneuronal itch targeting (Klirna), photoimmunotherapy (Nira), topical vitiligo therapy (Vimela), and dermatological supportive care for oncology patients (Graegis). Alys currently has two clinical-stage drug candidates: ALY-101, an intradermal injectable JAK1 siRNA-lipid conjugate in Phase 2a for alopecia areata that received FDA Fast Track designation; and ALY-301, a first-in-class cis-targeting bispecific antibody against c-Kit and CD203c in Phase 1/1b for chronic inducible urticaria (cold urticaria), being conducted at Charité Berlin. The broader pipeline comprises more than a dozen active programs targeting atopic dermatitis, vitiligo, psoriasis, chronic urticaria, mastocytosis, and CTCL, with a stated goal of delivering 7-10 clinical proof-of-concept readouts and at least one registrational program within three years of launch.

The company is pre-revenue and will generate future revenue through sales of FDA-approved pharmaceutical products in dermatology. Its near-term go-to-market motion is enterprise-field-sales-style distribution through clinical trial sites and, upon approval, traditional pharmaceutical channels including specialty dermatology clinics, hospitals, and pharmacies. Pricing has not been disclosed and will be determined at launch. Customer segments are defined by indication (patients with atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, mastocytosis, etc.) and prescriber base (dermatologists and clinical investigators). The company is led by co-founder and Acting COO Thibaud Portal (formerly Global Head of Research at Galderma), with Nobel Laureate Craig Mello, John Harris (Mass General Brigham), Brian Kim (Mount Sinai), Lars French (LMU Munich), Eric Deutsch (Gustave Roussy), and Mark Prausnitz (Georgia Tech) as scientific co-founders, and Francesco De Rubertis (Medicxi) as Executive Chairman.

Short descriptiontext

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing multi-platform immuno-dermatology treatments, with siRNA and bispecific antibody candidates in Phase 1/2 trials for alopecia areata and chronic urticaria, backed by Medicxi.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-dermatology therapeutics, siRNA drug development, bispecific antibodies, dermatology clinical pipeline, biopharmaceutical drug candidates
Industry2 codes
PRIMARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-dermatology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue clinical stage biotech company developing immuno-dermatology drugs. Revenue will be generated through sales of FDA-approved pharmaceutical products targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and mastocytosis.

alyspharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-dermatology drug candidates targeting inflammatory and autoimmune skin diseases. The pipeline includes ALY-101 (a JAK1 siRNA-lipid conjugate in Phase 2a for Alopecia Areata) and ALY-301 (a first-in-class mast cell-selective c-Kit bispecific antibody in Phase 1/1b for Chronic Urticaria), supported by more than a dozen active preclinical and clinical programs addressing atopic dermatitis, vitiligo, psoriasis, mastocytosis, and dermatological side effects of oncology therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ALY-101 showed durability in skin for over two months (Nature Communications publication)
+3 more records
Product overview1 text field

Alys Pharmaceuticals is a pure-play immuno-dermatology company structured as a multi-platform pipeline with six operating subsidiaries. The company operates two main clinical-stage drug candidates: ALY-101 (siRNA-lipid conjugate for Alopecia Areata, Phase IIa) and ALY-301 (bispecific antibody for Chronic Urticaria, Phase 1/1b). The portfolio includes platform technologies spanning siRNA therapeutics (Aldena Therapeutics), mast cell-targeted biologics (Granular Therapeutics), photoimmunotherapy (Nira Biosciences), intraneuronal itch targeting (Klirna Biotech), topical vitiligo therapy (Vimela Therapeutics), and dermatological supportive care for oncology patients (Graegis Pharmaceuticals). The company has more than a dozen active programs targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and systemic mastocytosis.

Product and service2 records
1ALY-101
CategoryDrug candidate
Description

An intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata. First clinical candidate from the siRNA platform developed with UMass Chan Medical School's RNA Therapeutics Institute, designed for precise target specificity, stability, enhanced skin affinity, and long-lasting clinical efficacy while minimizing systemic exposure. Received FDA Fast Track designation.

2ALY-301
CategoryDrug candidate
Description

A first-in-class cis-targeting bispecific antibody targeting c-Kit and CD203c, designed to selectively deplete mast cells for the treatment of Chronic Urticaria and other mast cell-driven diseases. The first mast cell-selective c-Kit inhibitor to enter the clinic, designed to enable safe chronic dosing while avoiding the safety limitations of conventional c-Kit inhibitors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key collaborating institution and home of co-founders John Harris (Chief Innovation Officer, Chair of Dermatology) and Craig Mello (Nobel Laureate, Blais University Chair in Molecular Medicine). Multi-year joint research with RNA Therapeutics Institute developing siRNA therapies. ALY-101 developed in collaboration with the RNA Institute of UMass Chan Medical School.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major European cancer research and treatment center. Co-founded by Eric Deutsch, Professor in Oncology and Radiotherapy at Université Paris-Saclay and Director of RHU LYSAIRI Project at Gustave Roussy. Collaborating on dermatology supportive care for cancer patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key collaborating institution and home of co-founder Mark Prausnitz (Regents' Professor, J. Erskine Love Professor of Chemical and Biomolecular Engineering). Partner for drug delivery technology using microneedles, lasers, ionic liquids and other microdevices.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Swiss Federal Laboratories for Materials Science & Technology. Collaborating institution for advanced materials and drug delivery research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Home of co-founder Brian Kim (Vice Chair of Research, Department of Dermatology, and Director of Mark Lebwohl Center for Neuroinflammation and Sensation). Head of Alys Pharmaceuticals Scientific Advisory Board.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Leading German research university hosting Phase 1/1b clinical trial of ALY-301 for Cold Urticaria. Professor Martin Metz from Charité serves as Principal Investigator for ALY-301 trial.

Strategic tierCoreTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals following merger. Specializes in siRNA technology for dermatological applications. Developed ALY-101 siRNA-lipid conjugate platform.

Strategic tierSupportingTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals. Dedicated to supporting skin and mucosa through cancer therapies and prevention of skin radiation damage in cancer patients treated with radiation therapy.

Strategic tierCoreTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals. Specializes in granulocyte-targeted therapy with mast cell-specific targeting. Developed ALY-301 mast cell-selective bispecific antibody platform.

Strategic tierSupportingTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals. Revolutionizing itch treatment through intraneuronal targeting of molecular switches of itch.

Strategic tierSupportingTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals. Developing photoimmunotherapy platform deployed toward immuno-dermatology with spatially defined, cell-targeted therapy using monoclonal antibody-targeted delivery.

Strategic tierSupportingTypeOthers
Description

One of six subsidiaries wholly owned by Alys Pharmaceuticals. Advancing topical therapy for vitiligo with orthogonal approach to current immunomodulatory options for repigmentation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology biotech developing antibodies for inflammatory diseases including atopic dermatitis, alopecia areata, and other immuno-dermatology indications. Directly comparable pipeline focus and development stage to Alys.

TypeEmerging player
Description

European-headquartered specialty dermatology biopharma with a focused portfolio of topical and systemic dermatology treatments. Comparable as a mid-sized dermatology pure-play, particularly given Alys's European operations in Switzerland and German clinical sites.

TypeBroad incumbent
Description

Global pharmaceutical major with Dupixent (dupilumab) co-developed with Regeneron — the dominant atopic dermatitis biologic. Sets the standard-of-care bar Alys's atopic dermatitis and chronic urticaria programs must clear, and a likely commercial partner or acquirer for late-stage assets.

TypeBroad incumbent
Description

Major biopharma with a significant immunology and dermatology franchise including Rinvoq (upadacitinib) and Skyrizi (risankizumab), both approved in atopic dermatitis and psoriasis. Competes head-to-head with Alys in immuno-dermatology indications and could be a commercial partner.

TypeBroad incumbent
Description

Pharmaceutical major with dermatology assets including Cibinqo (abrocitinib) and Litfulo (ritlecitinib) — JAK inhibitors directly relevant to Alys's alopecia areata (ALY-101) target. Granular Therapeutics CSO Orla Cunningham is a former Pfizer Senior Director, evidencing talent and competitive overlap.

TypeBroad incumbent
Description

Global pure-play dermatology company covering therapeutic, aesthetic, and consumer skin health. Multiple Alys executives (COO Thibaud Portal, Patrick Raboisson, Emmanuel Vial) are former Galderma R&D leaders, making it the most direct large-scale dermatology incumbent and a likely strategic acquirer or partner.

TypeDirect peer
Description

Specialty dermatology company developing therapeutics for skin diseases including molluscum contagiosum and common warts. Comparable as a small, focused dermatology biopharma targeting niche or underserved dermatology indications.

TypeDirect peer
Description

Specialty dermatology biopharma developing best-in-class topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis, psoriasis). Comparable to Alys as a clinical-stage dermatology pure-play with multiple approved/late-stage assets targeting immuno-dermatology indications.

TypeDirect peer
Description

Commercial-stage biopharma with Opzelura (ruxolitinib cream) — the first FDA-approved repigmentation therapy for vitiligo and a topical JAK inhibitor. Direct competitor to Alys's vitiligo and alopecia programs, and previously acquired Villaris Therapeutics (anti-IL-15 antibody for vitiligo) founded by Alys co-founder John Harris.

TypeDirect peer
Description

Specialty dermatology company developing novel topical therapeutics (Vtama/tapinarof) for psoriasis and atopic dermatitis. Closely comparable to Alys in business model and target indications within immuno-dermatology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alys Pharmaceuticals

Immuno-dermatology Pharmaceuticalsalyspharma.com

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing multi-platform immuno-dermatology treatments, with siRNA and bispecific antibody candidates in Phase 1/2 trials for alopecia areata and chronic urticaria, backed by Medicxi.

What Alys Pharmaceuticals does

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company focused exclusively on immuno-dermatology, founded in February 2024 through the strategic merger of six asset-centric Medicxi portfolio companies (Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences, and Vimela Therapeutics) with a $100 million seed financing from Medicxi. The company is headquartered in Boston, Massachusetts, with European operations in the Geneva/Lausanne area and operates through six wholly-owned subsidiaries that each maintain a distinct technology platform: siRNA-lipid conjugates (Aldena), mast cell-selective bispecific antibodies (Granular), intraneuronal itch targeting (Klirna), photoimmunotherapy (Nira), topical vitiligo therapy (Vimela), and dermatological supportive care for oncology patients (Graegis). Alys currently has two clinical-stage drug candidates: ALY-101, an intradermal injectable JAK1 siRNA-lipid conjugate in Phase 2a for alopecia areata that received FDA Fast Track designation; and ALY-301, a first-in-class cis-targeting bispecific antibody against c-Kit and CD203c in Phase 1/1b for chronic inducible urticaria (cold urticaria), being conducted at Charité Berlin. The broader pipeline comprises more than a dozen active programs targeting atopic dermatitis, vitiligo, psoriasis, chronic urticaria, mastocytosis, and CTCL, with a stated goal of delivering 7-10 clinical proof-of-concept readouts and at least one registrational program within three years of launch.

The company is pre-revenue and will generate future revenue through sales of FDA-approved pharmaceutical products in dermatology. Its near-term go-to-market motion is enterprise-field-sales-style distribution through clinical trial sites and, upon approval, traditional pharmaceutical channels including specialty dermatology clinics, hospitals, and pharmacies. Pricing has not been disclosed and will be determined at launch. Customer segments are defined by indication (patients with atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, mastocytosis, etc.) and prescriber base (dermatologists and clinical investigators). The company is led by co-founder and Acting COO Thibaud Portal (formerly Global Head of Research at Galderma), with Nobel Laureate Craig Mello, John Harris (Mass General Brigham), Brian Kim (Mount Sinai), Lars French (LMU Munich), Eric Deutsch (Gustave Roussy), and Mark Prausnitz (Georgia Tech) as scientific co-founders, and Francesco De Rubertis (Medicxi) as Executive Chairman.

Alys Pharmaceuticals firmographics

Firmographics
Name
Alys Pharmaceuticals
Legal name
Alys Pharmaceuticals, Inc.
Website
https://alyspharma.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing multi-platform immuno-dermatology treatments, with siRNA and bispecific antibody candidates in Phase 1/2 trials for alopecia areata and chronic urticaria, backed by Medicxi.
Ownership category
akta.pro rank

Alys Pharmaceuticals industry classification

Industry
Product category
Immuno-dermatology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Immuno-dermatology therapeutics
  • SiRNA drug development
  • Bispecific antibodies
  • Dermatology clinical pipeline
  • Biopharmaceutical drug candidates

Where Alys Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Alys Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Pre-revenue clinical stage biotech company developing immuno-dermatology drugs. Revenue will be generated through sales of FDA-approved pharmaceutical products targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and mastocytosis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Alys Pharmaceuticals product offering

Product offering

Core offering

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-dermatology drug candidates targeting inflammatory and autoimmune skin diseases. The pipeline includes ALY-101 (a JAK1 siRNA-lipid conjugate in Phase 2a for Alopecia Areata) and ALY-301 (a first-in-class mast cell-selective c-Kit bispecific antibody in Phase 1/1b for Chronic Urticaria), supported by more than a dozen active preclinical and clinical programs addressing atopic dermatitis, vitiligo, psoriasis, mastocytosis, and dermatological side effects of oncology therapies.

Product overview

Alys Pharmaceuticals is a pure-play immuno-dermatology company structured as a multi-platform pipeline with six operating subsidiaries. The company operates two main clinical-stage drug candidates: ALY-101 (siRNA-lipid conjugate for Alopecia Areata, Phase IIa) and ALY-301 (bispecific antibody for Chronic Urticaria, Phase 1/1b). The portfolio includes platform technologies spanning siRNA therapeutics (Aldena Therapeutics), mast cell-targeted biologics (Granular Therapeutics), photoimmunotherapy (Nira Biosciences), intraneuronal itch targeting (Klirna Biotech), topical vitiligo therapy (Vimela Therapeutics), and dermatological supportive care for oncology patients (Graegis Pharmaceuticals). The company has more than a dozen active programs targeting dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, chronic urticaria, psoriasis, and systemic mastocytosis.

Differentiator

Problem solved

Functional benefit

Products and services

  • ALY-101 An intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata. First clinical candidate from the siRNA platform developed with UMass Chan Medical School's RNA Therapeutics Institute, designed for precise target specificity, stability, enhanced skin affinity, and long-lasting clinical efficacy while minimizing systemic exposure. Received FDA Fast Track designation.
  • ALY-301 A first-in-class cis-targeting bispecific antibody targeting c-Kit and CD203c, designed to selectively deplete mast cells for the treatment of Chronic Urticaria and other mast cell-driven diseases. The first mast cell-selective c-Kit inhibitor to enter the clinic, designed to enable safe chronic dosing while avoiding the safety limitations of conventional c-Kit inhibitors.

Quantifiable outcome

  • ALY-101 showed durability in skin for over two months (Nature Communications publication)
  • +3 more outcomes

Companies that use Alys Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Alys Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alys Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and supporting.

  • UMass Chan Medical SchoolcoreStrategic or Co-development PartnerKey collaborating institution and home of co-founders John Harris (Chief Innovation Officer, Chair of Dermatology) and Craig Mello (Nobel Laureate, Blais University Chair in Molecular Medicine). Multi-year joint research with RNA Therapeutics Institute developing siRNA therapies. ALY-101 developed in collaboration with the RNA Institute of UMass Chan Medical School.
  • Gustave RoussycoreStrategic or Co-development PartnerMajor European cancer research and treatment center. Co-founded by Eric Deutsch, Professor in Oncology and Radiotherapy at Université Paris-Saclay and Director of RHU LYSAIRI Project at Gustave Roussy. Collaborating on dermatology supportive care for cancer patients.
  • Georgia Institute of TechnologycoreStrategic or Co-development PartnerKey collaborating institution and home of co-founder Mark Prausnitz (Regents' Professor, J. Erskine Love Professor of Chemical and Biomolecular Engineering). Partner for drug delivery technology using microneedles, lasers, ionic liquids and other microdevices.
  • Empa (Swiss Federal Laboratories for Materials Science & Technology)supportingStrategic or Co-development PartnerSwiss Federal Laboratories for Materials Science & Technology. Collaborating institution for advanced materials and drug delivery research.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerHome of co-founder Brian Kim (Vice Chair of Research, Department of Dermatology, and Director of Mark Lebwohl Center for Neuroinflammation and Sensation). Head of Alys Pharmaceuticals Scientific Advisory Board.
  • Charité – Universitätsmedizin BerlinsupportingStrategic or Co-development PartnerLeading German research university hosting Phase 1/1b clinical trial of ALY-301 for Cold Urticaria. Professor Martin Metz from Charité serves as Principal Investigator for ALY-301 trial.
  • Aldena TherapeuticscoreOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals following merger. Specializes in siRNA technology for dermatological applications. Developed ALY-101 siRNA-lipid conjugate platform.
  • Graegis PharmaceuticalssupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Dedicated to supporting skin and mucosa through cancer therapies and prevention of skin radiation damage in cancer patients treated with radiation therapy.
  • Granular TherapeuticscoreOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Specializes in granulocyte-targeted therapy with mast cell-specific targeting. Developed ALY-301 mast cell-selective bispecific antibody platform.
  • Klirna BiotechsupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Revolutionizing itch treatment through intraneuronal targeting of molecular switches of itch.
  • Nira BiosciencessupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Developing photoimmunotherapy platform deployed toward immuno-dermatology with spatially defined, cell-targeted therapy using monoclonal antibody-targeted delivery.
  • Vimela TherapeuticssupportingOthersOne of six subsidiaries wholly owned by Alys Pharmaceuticals. Advancing topical therapy for vitiligo with orthogonal approach to current immunomodulatory options for repigmentation.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Alys Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • AnaptysBio: Clinical-stage immunology biotech developing antibodies for inflammatory diseases including atopic dermatitis, alopecia areata, and other immuno-dermatology indications. Directly comparable pipeline focus and development stage to Alys.
  • Verrica Pharmaceuticals: Specialty dermatology company developing therapeutics for skin diseases including molluscum contagiosum and common warts. Comparable as a small, focused dermatology biopharma targeting niche or underserved dermatology indications.
  • Arcutis Biotherapeutics: Specialty dermatology biopharma developing best-in-class topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis, psoriasis). Comparable to Alys as a clinical-stage dermatology pure-play with multiple approved/late-stage assets targeting immuno-dermatology indications.
  • Incyte Corporation: Commercial-stage biopharma with Opzelura (ruxolitinib cream) — the first FDA-approved repigmentation therapy for vitiligo and a topical JAK inhibitor. Direct competitor to Alys's vitiligo and alopecia programs, and previously acquired Villaris Therapeutics (anti-IL-15 antibody for vitiligo) founded by Alys co-founder John Harris.
  • Dermavant Sciences: Specialty dermatology company developing novel topical therapeutics (Vtama/tapinarof) for psoriasis and atopic dermatitis. Closely comparable to Alys in business model and target indications within immuno-dermatology.

Emerging players

  • Almirall: European-headquartered specialty dermatology biopharma with a focused portfolio of topical and systemic dermatology treatments. Comparable as a mid-sized dermatology pure-play, particularly given Alys's European operations in Switzerland and German clinical sites.

Broad incumbents

  • Sanofi: Global pharmaceutical major with Dupixent (dupilumab) co-developed with Regeneron — the dominant atopic dermatitis biologic. Sets the standard-of-care bar Alys's atopic dermatitis and chronic urticaria programs must clear, and a likely commercial partner or acquirer for late-stage assets.
  • AbbVie: Major biopharma with a significant immunology and dermatology franchise including Rinvoq (upadacitinib) and Skyrizi (risankizumab), both approved in atopic dermatitis and psoriasis. Competes head-to-head with Alys in immuno-dermatology indications and could be a commercial partner.
  • Pfizer: Pharmaceutical major with dermatology assets including Cibinqo (abrocitinib) and Litfulo (ritlecitinib) — JAK inhibitors directly relevant to Alys's alopecia areata (ALY-101) target. Granular Therapeutics CSO Orla Cunningham is a former Pfizer Senior Director, evidencing talent and competitive overlap.
  • Galderma: Global pure-play dermatology company covering therapeutic, aesthetic, and consumer skin health. Multiple Alys executives (COO Thibaud Portal, Patrick Raboisson, Emmanuel Vial) are former Galderma R&D leaders, making it the most direct large-scale dermatology incumbent and a likely strategic acquirer or partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Alys Pharmaceuticals social profiles

Digital presence

Alys Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alys Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles19 records

Alys Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Alys Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alys Pharmaceuticals M&A and investment

M&A and investment

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alys Pharmaceuticals

What does Alys Pharmaceuticals do?

Alys Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-dermatology drug candidates targeting inflammatory and autoimmune skin diseases. The pipeline includes ALY-101 (a JAK1 siRNA-lipid conjugate in Phase 2a for Alopecia Areata) and ALY-301 (a first-in-class mast cell-selective c-Kit bispecific antibody in Phase 1/1b for Chronic Urticaria), supported by more than a dozen active preclinical and clinical programs addressing atopic dermatitis, vitiligo, psoriasis, mastocytosis, and dermatological side effects of oncology therapies.

Is Alys Pharmaceuticals a public or private company?

Alys Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alys Pharmaceuticals founded?

Alys Pharmaceuticals was founded in 2024. It employs 1 to 10 people.

Where is Alys Pharmaceuticals based?

Alys Pharmaceuticals is headquartered in Boston, United States, in the North America region.

How does Alys Pharmaceuticals make money?

One revenue line is on record: pharmaceutical product sales.

Who are Alys Pharmaceuticals's main competitors?

Direct peers on record are AnaptysBio, Verrica Pharmaceuticals, Arcutis Biotherapeutics, Incyte Corporation and Dermavant Sciences. Almirall is listed as an emerging player. Broad incumbents are Sanofi, AbbVie, Pfizer and Galderma.

Does Alys Pharmaceuticals have an API?

No public API is recorded for Alys Pharmaceuticals.

What industry is Alys Pharmaceuticals in?

Alys Pharmaceuticals's product category is Immuno-dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAM, Rare Dermatology Disorder Therapies, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireChronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsightDelveInsight's chronic urticaria pipeline report covers 20+ companies developing 30+ drugs, with 12+ in late or mid stages. Recent milestones include Celldex's Phase III enrollment of 1,939 patients and Enanta's first-dose of EDP-978. The report also notes positive Phase I results from Septerna and Highlightll.startupticker.chTwo publications and an FDA fast track designation for Swiss biotechsMoonLake Immunotherapeutics has received FDA Fast Track designation for sonelokimab in treating moderate to severe palmoplantar pustulosis, based on positive Phase 2 LEDA trial results, accelerating the development timeline for this IL-17 inhibitor. Alys Pharmaceuticals published in Nature Communications on its siRNA-lipid conjugate ALY-101 showing durability in skin for over two months, currently in Phase 2a trials for alopecia areata. iOnctura published in Molecular Oncology on roginolisib, a PI3Kδ modulator now being evaluated across multiple Phase I/II studies in uveal melanoma, NSCLC, CLL, myelofibrosis, and PTCL with over 170 patients treated.PharmiWeb.comAlys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic UrticariaAlys Pharmaceuticals has dosed the first subject in a Phase 1/1b clinical trial of ALY-301, a first-in-class mast cell selective c-Kit bispecific inhibitor being developed for Cold Urticaria. The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, and pharmacology in healthy volunteers and patients who remain symptomatic despite antihistamines, with initial data readouts expected in 2026. This marks Alys's second clinical program initiated in 2025 and the first from the Company's Granular platform, positioning the immuno-dermatology company as a pioneer in targeting mast cell-driven dermatological diseases.PR NewswireAlys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for Chronic UrticariaAlys Pharmaceuticals has dosed the first subject in a Phase 1/1b clinical trial for ALY-301, a first-in-class mast cell selective c-Kit inhibitor designed to treat Chronic Urticaria. The multicenter study, initiated at Charité–Universitätsmedizin Berlin with planned expansion across Germany, aims to evaluate the drug's safety and efficacy in healthy volunteers and patients. Initial data readouts from this trial are expected in 2026.PharmaTimesAlys Pharmaceuticals begins phase 1/1b trial of ALY-301 for chronic urticariaAlys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast cell selective c-Kit inhibitor developed for the treatment of Cold Urticaria. The multicentre study will enrol both healthy volunteers and patients, with initial data expected in 2026. Company executives and investigators highlighted the transformative potential of this precision-targeted therapy in the immune-dermatology space.PR NewswireAlys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia AreataAlys Pharmaceuticals has announced the dosing of the first patient in its Phase IIa trial of ALY-101, a JAK1-targeting siRNA-lipid conjugate formulated as an intradermal injectable for Alopecia Areata, a chronic autoimmune disease causing significant psychological distress. The trial will assess safety and tolerability with injections every four weeks over eight weeks, with topline results expected in 2026. The company, backed by $100M financing from Medicxi, remains on track to deliver multiple clinical Proof-of-Concept readouts by 2027 and is also developing a trans-epidermal formulation for atopic dermatitis and vitiligo.ContractpharmaIntroducing Alys Pharmaceuticals: A New Immuno-Dermatology Focused CompanyAlys Pharmaceuticals, an immuno-dermatology company, launched with a $100 million financing from Medicxi. It combines assets from six Medicxi companies and has over a dozen active programs targeting atopic dermatitis, vitiligo, and other indications. The company aims to deliver seven to ten clinical proof-of-concept readouts over three years.startupticker.chMedicxi invests $100 million in newly launched Alys PharmaceuticalsMedicxi has invested $100 million in Alys Pharmaceuticals, a newly formed entity created by consolidating six existing Medicxi biotech companies. The new company is focused on immuno-dermatology with a pipeline of 14 programs targeting conditions such as atopic dermatitis and psoriasis, while establishing operational bases in Boston and Geneva.VC News DailyAlys Pharmaceuticals Launches with $100M FinancingAlys Pharmaceuticals has launched with a focus on immuno-dermatology, supported by a $100 million financing round led by Medicxi. The company is built on technology from six different Medicxi companies and aims to develop a range of innovative dermatological treatments. This launch marks a significant step in expanding Alys's R&D capabilities in the dermatology sector.